Johnson & Johnson (JNJ) Announces Additional FDA Indication for EVARREST Fibrin Sealant Patch

< span style= " color: #444444; font-family: Verdana, sans-serif; " > Johnson & amp; Johnson (NYSE: JNJ) announced the following Monday: < /span > < br / > < span style= " color: #444444; font-family: Verdana, sans-serif; " > < br / > < /span > < span style= " color: #444444; font-family: Verdana, sans-serif; " > Unexpected and uncontrollable bleeding is an ongoing challenge for surgeons, including those who perform liver surgery. Based on recent data, the U.S. Food and Drug Administration has approved an additional indication for Ethicon ' s EVARREST Fibrin Sealant Patch, as an adjunct to hemostasis for control of bleeding during adult liver surgery. EVARREST is a novel convergence of biologics and medical device that rapidly and reliably stops problematic bleeding during surgery on the first attempt in indicated patients. < /span > < br / > < span style= " color: #444444; font-family: Verdana, sans-serif; " > < br / > < /span > < span style= " color: #444444; font-family: Verdana, sans-serif; " > A problematic bleeding situation —involving bleeding that is more than routine and resistant to conventional means of control—is one of the most threatening complications of surgery1 and a frequent cause of negative patient outcomes, posing significant clinical and economic challenges.2,3 First attempts to control surgical blee ding using current hemostatic agents can fail up to 50 percent of the time.3 < /span > < br / > < span style= " color: #444444; font-family: Verdana, sa...

Source: Medical Hemostat - April 5, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs